09:16 AM EDT, 05/15/2025 (MT Newswires) -- Sellas Life Sciences Group ( SLS ) said Thursday it has dosed the first pediatric patient in the ongoing phase 2 trial of SLS009 in relapsed/refractory acute myeloid leukemia.

The study will assess the safety, tolerability and efficacy of SLS009 in combination with venetoclax and azacitidine at doses of 45 and 60 mg, the company said.

The company said it received the Rare Pediatric Disease Designation for the program from the Food and Drug Administration for the treatment of pediatric acute myeloid leukemia last year.